Teladoc (NYSE:TDOC) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of -$0.43 to -$0.45 for the period, compared to the Thomson Reuters consensus estimate of ($0.38). The company issued revenue guidance of $86 million to $88 million, compared to the consensus revenue estimate of $83.76 million.Teladoc also updated its FY18 guidance to -$1.36 to -$1.41 EPS.
Shares of Teladoc (TDOC) traded up $0.15 during trading hours on Wednesday, reaching $42.95. The company’s stock had a trading volume of 1,028,778 shares, compared to its average volume of 1,183,508. Teladoc has a 52-week low of $21.25 and a 52-week high of $44.65. The company has a market capitalization of $2,610.00 and a PE ratio of -20.77. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.37.
TDOC has been the topic of a number of analyst reports. Canaccord Genuity upped their price target on Teladoc from $42.00 to $43.00 and gave the company a buy rating in a research report on Wednesday, January 31st. Oppenheimer upped their price target on Teladoc from $40.00 to $45.00 and gave the company an outperform rating in a research report on Tuesday, November 21st. Chardan Capital reiterated a buy rating and issued a $47.00 price target (down from $48.00) on shares of Teladoc in a research report on Wednesday, February 28th. ValuEngine upgraded Teladoc from a sell rating to a hold rating in a research report on Friday, February 2nd. Finally, Cantor Fitzgerald reiterated a hold rating and issued a $35.00 price target (up from $31.00) on shares of Teladoc in a research report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $40.71.
In other news, President Peter A. Mcclennen sold 27,533 shares of the company’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $43.01, for a total transaction of $1,184,194.33. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Andrew Turitz sold 36,210 shares of the company’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $40.39, for a total value of $1,462,521.90. Following the transaction, the senior vice president now directly owns 16,700 shares in the company, valued at approximately $674,513. The disclosure for this sale can be found here. In the last three months, insiders sold 324,494 shares of company stock worth $12,935,147. Insiders own 4.47% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/03/14/teladoc-tdoc-issues-q1-earnings-guidance.html.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.